Effect of adriamycin, 5-fluorouracil and mitomycin-C combination chemotherapy in advanced colorectal cancer.
One hundred and seventy-four patients with advanced colorectal cancer were treated with 5-fluorouracil (5-FU), mitomycin-C (MIT-C) and Adriamycin (ADR) (FAM). The total response rate was 26.4%. A higher response rate (37%) was observed in patients with liver metastases only, compared to other sites of metastases (p < 0.02). Complete remission were achieved only in patients with liver metastases (15%). Male patients with liver metastases had a higher response rate than females (p < 0.03). Twenty-five patients previously treated unsuccessfully with 5-FU and MIT-C showed a response rate of 28% when ADR was added to the regimen. The patients' median survival was 11 months (range: from 3 to > or = 60 months). The median survival of patients with liver metastases was 11 months and that of responders (20 months) was significantly longer than that of nonresponders (7 months; p < 0.0001). These results suggest that the FAM combination might be considered an eligible chemotherapy schedule for patients with liver metastatic disease from colorectal cancer.